Action INMB INMUNE BIO, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués INmune Bio, Inc.

Actions

INMB

US45782T1051

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 26/06/2024 		Varia. 5j. Varia. 1 janv.
7,29 USD +1,96% Graphique intraday de INmune Bio, Inc. -5,32% -35,26%
30/05 Mise à jour sectorielle : Les actions du secteur de la santé en hausse dans l'après-midi MT
30/05 INmune Bio rejoindra l'indice Russell 3000 en juillet MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
INmune Bio Inc. to Join Russell 3000® Index
GL
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
AQ
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
GL
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
AQ
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
GL
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
GL
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GL
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AQ
INmune Bio Inc. Announces 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling and Development of Novel Immunogenicity Assay
AQ
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
AQ
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
GL
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
GL
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
GL
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
AQ
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
AQ
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
GL
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
GL
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
AQ
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
GL
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GL
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action INMB
  4. Actualités INmune Bio, Inc.
  5. Communiqués